Skip to main content

Biological Aging

0
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Abbott
AbbottABBOTT PARK, IL
1 program
Catechin Cohort 1N/A1 trial
Active Trials
NCT03213340Completed39Est. Oct 2019
Elysium Therapeutics
1 program
The Translational Initiative to Map Epigenetics in Aging (TIME-A)N/A1 trial
Active Trials
NCT05760547Not Yet Recruiting25,000Est. Mar 2033

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Elysium TherapeuticsThe Translational Initiative to Map Epigenetics in Aging (TIME-A)
AbbottCatechin Cohort 1

Clinical Trials (2)

Total enrollment: 25,039 patients across 2 trials

NCT05760547Elysium TherapeuticsThe Translational Initiative to Map Epigenetics in Aging (TIME-A)

The Translational Initiative to Map Epigenetics in Aging (TIME-A)

Start: Mar 2023Est. completion: Mar 203325,000 patients
N/ANot Yet Recruiting
NCT03213340AbbottCatechin Cohort 1

Effects of Phytonutrients Upon Muscle Perfusion in Response to Feeding

Start: Sep 2017Est. completion: Oct 201939 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.